
| Tuesday's Markets | |
|---|---|
| S&P 500 7,139 (-0.49%) |
|
| Nasdaq 24,664 (-0.90%) |
|
| Dow 49,142 (-0.05%) |
|
| Bitcoin $76,352 (-0.76%) |
|

| Tuesday's Markets | |
|---|---|
| S&P 500 7,139 (-0.49%) |
|
| Nasdaq 24,664 (-0.90%) |
|
| Dow 49,142 (-0.05%) |
|
| Bitcoin $76,352 (-0.76%) |
|
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Wake up to the latest market news, company insights, and a bit of Foolish fun -- all wrapped up in one quick, easy-to-read email, called Breakfast News. Delivered at 7:30 a.m. ET every single market day. See an example of our weekday Breakfast News email & sign-up below.
Enphase Energy (NASDAQ:ENPH) dropped more than 10% in pre-market trading after posting a 31% year-over-year (YOY) fall in non-GAAP earnings per share for its fiscal first quarter. Recommended in Stock Advisor by Team Rule Breakers, the maker of solar energy technology saw U.S. revenue fall sharply against a backdrop of tariff costs and oil-focused energy priorities. Tougher domestic trading was offset in part by international expansion.
By Tom Gardner, TMF co-founder and CEO, Team Hidden Gems
Kiniksa (NASDAQ:KNSA) is now a profitable, fast-growing biotech with a clear compounding path. ARCALYST is driving 50%+ growth w/rising adoption, expanding prescribers, and multi-year patient use. This creates durable, recurring-like revenue. Penetration is still early, with meaningful upside as usage moves earlier in treatment. The company is reinvesting smartly. They're driving AI-powered marketing w/targeted outreach. This should continue to accelerate growth. Its pipeline (KPL-387, KPL-1161) is designed to extend rather than disrupt the franchise with better dosing and convenience. Lots of cash generation oncoming and a large remaining market, Kiniksa is evolving into a long-term pharma franchise. It really is not a one-drug story.
Which two of the "Magnificent Seven" do you think will be the best performers over the next five years, and why?
Debate with friends and family, or become a member to hear what your fellow Fools are saying!